关键信息
-
基因名
VEGFR-1
- 应用
-
别名
Flt1; Fms-Related Tyrosine Kinase 1; Vascular Permeability Factor Receptor; Fms-like tyrosine kinase 1; Tyrosine-protein kinase receptor FLT
-
种属
Pig
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
ACH73486.1
-
表达区间
Pro167~Ala424
-
分子量
59kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) is a critical receptor involved in angiogenesis, the formation of new blood vessels from pre-existing ones, which plays a significant role in various physiological and pathological processes, including cancer progression, tissue repair, and embryonic development. The overexpression of VEGFR-1 has been associated with tumor growth and metastasis, making it a potential target for cancer therapy. Research on recombinant VEGFR-1 proteins has surged as scientists aim to better understand its structure, function, and mechanisms of action. These studies often involve the production of recombinant VEGFR-1 proteins in various expression systems, allowing for in-depth analysis of their biochemical properties, ligand-binding abilities, and downstream signaling pathways. By elucidating the interactions between VEGFR-1 and its ligands, researchers hope to identify novel therapeutic strategies, including monoclonal antibodies or small-molecule inhibitors that can disrupt VEGFR-1 signaling, potentially leading to improved clinical outcomes in cancer treatment and other diseases linked to aberrant angiogenesis. Moreover, recombinant VEGFR-1 proteins serve as valuable tools for screening and development of anti-angiogenic drugs, providing insights into their efficacy and safety profiles. Overall, the study of recombinant VEGFR-1 not only enhances our understanding of vascular biology but also opens avenues for innovative therapeutic approaches targeting angiogenesis-related disorders.
